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nase alfa therapy. A lung function test (“index”) separated a 2-year pre-index pe-
riod from a 2-year post-index period for which intercepts and slopes were
independently estimated. The comparator group included patients not yet re-
ported to have received dornase alfa; their index lung function test was associated
with their eighth or subsequent even-numbered birthday. Comparator patients
could contribute more than one set of pre- and post-index periods and could also
subsequently be included in the dornase alfa group. To account for the repeated
use of patients, variance components were estimated at the patient level as well as
the case level. Different subsets of the comparator cases were analyzed. RESULTS:
There were 2230 dornase alfa patients; the comparator group included 5970 cases
from 3517 patients. The estimated difference in change in slope was 0.73.31
(P0.020). Subsetting comparators to 4985 cases from 2836 patients not also in the
dornase alfa group gave 0.610.32 (P0.058); including each of those patients only
the last time eligible gave 0.680.36 (P0.059). Subsetting to 3662 cases from 2030
patients never on dornase alfa gave 0.320.34 (P0.35). Patient-level variance com-
ponents corresponding to difference in slope and difference in intercept were near
zero and so were dropped. CONCLUSIONS: In longitudinal observational studies,
patients should be included in each group for which they meet eligibility criteria,
possibly multiple times (with appropriate covariance structures). This avoids bias
from using future information to decide whether to include a patient and loss of
power from limiting cases unnecessarily.
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Numerous assumptions and techniques are necessary to perform meta-analysis.
Some overall structural guidelines and best practices on meta-analysis exist. How-
ever, few papers compare meta-analysis techniques in application. OBJECTIVES:
To review primary meta-analysis methods and their assumptions. After method-
ology review, we applied various meta-analysis techniques to the data of various
Bacille Calmette Guerin (BCG) vaccine studies and compared the results.
METHODS: Of the currently available meta-analysis techniques, the most basic
technique was applied first. Fixed effect models assume treatment effect homoge-
neity across studies. Then, random effect models and meta-regression were ex-
plored. Each technique explicitly models treatment heterogeneity. Lastly, the pos-
sibility of publication bias was tested through the use of a funnel plot. RESULTS:
Treatment effect estimates differed depending on the meta-technique applied.
When a fixed effect model was applied to estimate vaccination effectiveness
against tuberculosis, the log odds ratio was0.436 (confidence interval [CI]:0.528,
0.344). After testing for heterogeneity and fitting a random effects model, the
estimate was reduced to 0.741 (CI: 1.120, 0.352), and the CI became wider.
When covariates were added to the model to explain the heterogeneity, the effect
of treatment was reduced even further. CONCLUSIONS: Meta-analysis results are
sensitive to the selected studies and the methodology applied. Ensuring that
proper techniques are used is critical to estimate an unbiased outcome.
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OBJECTIVES: The ISPOR Task force (TF) on Good Research Practices for RCT-CEA
aims to foster improvements in the conduct of trial-based economic analysis. The
TF recognizes the sample size of randomized clinical trials (RCT) as one of the
challenges for trial-based economic analysis, as it is typically based on the primary
clinical outcomes only. In the case of vitreomacular traction (VMT), using RCT
individual patient-level data (IPD) to establish model starting distributions within
visual acuity (VA) health-states magnifies this challenge due to the small patient
numbers within each relevant VA health-state. Our objective was to develop an
innovative approach to robustly estimate patient within-category VA health-state
starting distributions.METHODS:A baseline VA-adjusted ordered logit model used
RCT IPD to predict a patient’s VA starting distribution as a function of treatment
allocation, macular hole, vitreomacular adhesion and previous vitrectomy status.
The observed ordinal variable consisted of 6 response categories i.e. VA state as a
function of an unmeasured, continuous, latent variable Y whose values determine
the patient’s VA-state dependent specific VA thresholds. RESULTS: Treatment al-
location was not a significant predictor for within-category VA health-state start-
ing distributions (at the 5% significance level), while MH, VMA and previous vitrec-
tomy status were significant and retained in the final model. The proportional odds
assumption was tested using a likelihood ratio test and confirmed that the rela-
tionship between each pair of VA health-states was the same (chi2  0.0906).
CONCLUSIONS: In eye-disorders like VMT, estimating within-category VA health-
state starting distributions requires a different approach due to the small number
of IPD in each VA health-state. Using an ordered logit model allows a more accurate
and robust estimation of within-category VA health-state starting distributions.
Macular hole, VMA and previous vitrectomy status were significant predictors of a
patient’s within-category VA health-state starting distribution, while treatment
allocation was not.
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OBJECTIVES: With the lack of alternative strategies for calculating the dose of
cytotoxic drugs in chemotherapy regimens, body surface area (BSA), despite well-
documented limitations, remains the most frequently used measure for dosing
guidelines. This is based on the assumption that physiological variables related to
drug metabolism and elimination, such as basal metabolic rate, renal and hepatic
function, vary between individuals according to BSA. BSA has traditionally been
calculated using a formula derived from Du Bois and Du Bois and published in 1916.
It is recognised this is probably not the most accurate method of calculating che-
motherapy doses, since the formula was derived from metabolic studies using a
small number of subjects. The practice of calculating chemotherapy dose adjusted
to BSA has drawn attention due to its lack of clear scientific basis, and lack of
applicability to different genders, disease states, and culture.METHODS:A system-
atic literature review was conducted using CRD methodology to establish the av-
erage BSA in cancer patients in Europe and the variability between genders, tumour
types, and cultures. RESULTS: Meta-analysis of the findings showed significant
differences between genders overall (females 1.72m2 vs males 1.88m2), between
different tumour types (range 1.68m2 to 1.93m2) and between different European
countries (range 1.74m2 to 1.83m2). However, statistical modelling showed that a
BSA of 1.80m2 approximated the population mean and identified the dispersion to
be 1.72-1.87m2 and was therefore a valid approximation for the majority of cancer
patients in Europe. CONCLUSIONS: Establishing a patient’s BSA is important in
determining the appropriate dosage regimen, but the population norm serves as a
useful basis for drugs administered in a fixed dose formulation.
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OBJECTIVES: In the context of today’s highly globalized environment, the interest
in the transferability of data of cost evaluation in health care has strongly intensi-
fied. A methodology is proposed to explore similarity versus dissimilarity of cost
evaluation data in adult sarcoma and hence their transferability across locations
(France and Italy). METHODS: Main steps are (i) definition of the objects (e.g. coun-
tries), identification of potential variability factors, selection of final variability fac-
tors, and construction of variability areas (e.g. unit cost of personnel); (ii) measure
of distances between the objects, determination of clusters and construction of a
hierarchical tree using the cluster analysis (CA); (iii) projection of the objects into
factorial planes and linkage between objects and areas of variability using principal
component analysis (PCA). Suggested methods are applied to an international cost
evaluation performed within the European network of excellence CONnectiveTIs-
suesCAncersNETwork (CONTICANET). RESULTS: Twelve objects and 16 areas of
variability were defined. CA shows four clusters meaning that data belonging to
different clusters are dissimilar (i) chemotherapy in France, (ii) follow-up with
relapse in Italy, (iii) diagnosis, surgery, chemotherapy, radiotherapy, and follow-up
without relapse in Italy, (iv) diagnosis, surgery, radiotherapy, follow-up without
relapse, and follow-up with relapse in France. PCA opposes (i) follow-up with re-
lapse in Italy to diagnosis, radiotherapy, and follow-up with relapse in France; (ii)
chemotherapy in France to follow-up without relapse in France. In sarcoma pa-
tients, transferability is then limited for chemotherapy during the initial treatment
in France and the follow-up with relapse in Italy. Diagnosis cannot be transferred
either between France and Italy regarding the quantities and unit costs of the
biopsies. CONCLUSIONS: Using CA and PCA enables health care professionals to
rapidly emphasize the variability of data and therefore to determine the transfer-
ability of cost evaluations across locations.
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OBJECTIVES: To investigate the knowledge, awareness and attitudes of cardiolo-
gists about the risk and benefits associated with medicines and medical devices
and equipment, and of how well they are regulated and communicated in Turkey.
METHODS:An on –line questionnaire has been developed which include questions
about the level of education and experience; perceptions of the risks and benefits
associated with medicines and medical devices; experiences of medicines and
medical devices; perceptions of and attitudes towards the regulation of medicines
and medical devices; attitudes towards the communication of information about
the risks and benefits associated with medicines and medical devices; usage of and
trust in communication of information about the risks and benefits associated with
medicines and medical devices. RESULTS: A total of 250 members of the Turkish
A486 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
Society of Cardiology responded to the on – line questionnaire. The majority of
respondents agree that medical devices and equipment are not adequately regu-
lated at the moment in Turkey. Moreover they believe that manufacturing compa-
nies have too much influence on how medical devices and equipment are regu-
lated. The majority of the cardiologists value recommendations from colleagues.
When making risk/benefit decisions, surgeons rely on sharing information about
the merits and drawbacks of particular devices within their local peer groups,
especially Turkish Society of Cardiology, rather than using more formal avenues.
Cardiologists would be most likely to turn to the risk assessment unit at the hos-
pital they work for. Then they woul like to report the adverse events to the Ministry
of Health of Turkey General Directorate of Pharmaceuticals and Pharmacy, which
is the main regulating institution in Turkey. CONCLUSIONS: The qualitative anal-
ysis results indicate that efforts should be directed to inform cardiologists about
the functioning of General Directorate of Pharmaceuticals and Pharmacy and the
guidelines of medical device regulations.
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OBJECTIVES: Clinical trial publications commonly report only adverse event (AE)
rates occurring above an arbitrary threshold. Our objective was to devise a meta-
analysis technique that allowed trials to be included even when AE rates fell below
thresholds. METHODS: A maximum likelihood simulation (MLS) was devised that
assumed all AE trial results lay in the same binomial distribution truncated by
reporting thresholds. AE data from osteoarthritis trials were retrieved. The MLS
was executed using the random number generator and binomial distribution func-
tion of CafeSim, a Java modeling toolkit. Ten million iterations, needed for conver-
gence, were run for each tenth of a percent up to the highest rate reported. For each
iteration the values generated from the binomial function were compared to the
published AE rates and/or thresholds. The rate with the most matches was desig-
nated the point estimate (PE). The range from the 2.5 to 97.5 percentiles of matches
was the 95% confidence interval (CI). Verification was conducted for 2 AEs of 2
compounds. Results for 2 AEs reported in all etoricoxib trials were compared to
Comprehensive Meta-Analysis (CMA) results. Results for 2 AEs below reporting
thresholds of one or more diclofenac trials were compared to results from equiva-
lent SAS code using RANBIN and PROC FREQ. RESULTS: The MLS estimated PEs and
CIs for the etoricoxib AEs within 0.001 of CMA (hypertension PE  0.058 (0.059 for
MLS), CI [0.051, 0.065]). The MLS executed in CafeSim estimated PEs and CIs for the
diclofenac AEs within 0.002 of those estimated in SAS, identical for hypertension,
(PE  0.027, CI [0.022, 0.032]). When trials reported widely differing rates the MLS
converged slowly. The MLS estimated 0.000 when no trials reported the AE rate.
CONCLUSIONS:An MLS technique assuming a common binomial distribution may
provide a useful estimate of AE rates when they occasionally fall below reporting
thresholds.
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INTRODUCTION: An Excel calculator tool was created to perform meta-analysis in
a rapid manner. The tool performs both direct and indirect treatment comparisons.
A recent meta-analysis study examining rheumatoid arthritis (RA) was replicated
using the calculator. OBJECTIVES: To quickly perform meta-analyses, both direct
and indirect treatment comparisons, using Microsoft Excel. METHODS: We used a
random effects DerSimonian and Laird model by inputting the number of studies
and binary outcomes variables to report the Relative Risk (RR) for each study and a
pooled overall RR. The Q-statistic and the I-squared statistic were used to examine
heterogeneities across studies. Indirect treatment comparisons between specific
studies were performed post hoc. Indirect pair-wise comparisons were also per-
formed between studies. RESULTS: Three studies (Lipsky, Keystone, and Klares-
kog) were examined, comparing a combination of tumor necrosis factor (TNF) in-
hibitors plus methotrexate (MTX) to MTX monotherapy. Each study was evaluated
using the number of patients achieving American College of Rheumatology (ACR)
scores 20, 50, and 70. To test the Excel calculator, the number of patients obtaining
ACR20 scores was used in the replication. The overall RR was 1.89 (95% CI: 0.89,
4.00), which was not statistically significant (p-value0.10). There were significant
heterogeneities across treatments and the I-squared statistic was 96.2% (p-
value0.000). The Lipsky and Keystone studies had statistically significant treat-
ment effects relative to the Klareskog trial: Lipsky vs. Klareskog: RR 2.23 (95% CI:
1.37, 3.64, p-value0.001); Keystone vs. Klareskog: RR 2.17 (95% CI: 1.63, 2.89,
p-value0.001).CONCLUSIONS: The meta-analysis Excel calculator is a simple and
quick way to run random effect models with binary data. The replication output
matched the results of the original paper.
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OBJECTIVES: To compare indirect and MTC meta-analysis techniques used in the
evaluation of the protease inhibitors, boceprevir and telaprevir, in combination
with peginterferon alfa and ribavirin for the treatment of patients with genotype 1
chronic Hepatitis C. METHODS: A systematic search of the literature was con-
ducted in EMBASE and MEDLINE (January 2008 to May 2012) to identify studies that
utilised either indirect or MTC meta-analysis techniques to derive the relative
treatment effect between boceprevir and telaprevir. A qualitative comparison was
made between the methodologies and results of the identified studies. RESULTS:
Two publications were identified: a conference poster (Diels et al.) and a full publi-
cation (Cooper et al.). The main difference between the methodologies is that Coo-
per et al. used an adjusted indirect comparison and a random-effects MTC model
whereas Diels et al. used a fixed-effects MTC model. Diels et al. included three
further studies that compare peginterferon alfa-2a and alfa-2b without active ther-
apies. Cooper et al. conducted a random-effects adjusted indirect comparison that
included two additional telaprevir trials that were excluded from Diels et al. The
primary outcome in both studies was the proportion of patients achieving sus-
tained virologic response. Diels et al. reported no significant difference in treatment
naive patients and a significant effect in favour of telaprevir for treatment experi-
enced patients. When Diels et al. applied a random-effects model the effect of
telaprevir being superior in treatment experienced patients was non-significant.
The results reported by Cooper et al. showed no significant difference between
boceprevir and telaprevir, and did not vary in sensitivity analyses. CONCLUSIONS:
Comparison of these two studies highlights considerable methodological differ-
ences between the two approaches, which result in differing conclusions. While
MTC methods are growing in popularity and importance, certain nuances of ap-
proaches can result in important differences in interpretation.
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OBJECTIVES: To extend well-established methods for sample size in power calcu-
lations in pair wise meta-analysis to the scenario where multiple treatments are
being analyzed in a network meta-analysis METHODS: We derive methods of ap-
proximating the ‘effective number of patients’ in indirect comparison meta-anal-
ysis where no head-to-head evidence is available. We calibrate these approaches
with conventional approaches for estimating the required sample size and power
in pair wise meta-analysis. RESULTS: The calibration of the above two methods
allow for a simple assessment of the power and strength of evidence for each
treatment comparison in a network of treatments. The resulting measures are 1)
the statistical power associated with each treatment comparison made in a net-
work meta-analysis; 2) the effective number of patients for each comparison con-
trasted, which can be contrasted with the required sample size for the particular
comparison to gauge the strength of evidence. We provide an illustrative example
using data from a network meta-analysis of interventions for smoking cessation.
CONCLUSIONS: The proposed measured follow the format of well-known sample
size and power measures. They are easy to calculate and will resonate with a
statistically non-sophisticated audience.
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OBJECTIVES: This research uses a comparative analysis framework between na-
tional health care systems and continues the theoretical development of the 3P
theory. It demonstrates that sets of cost reduction strategies and by physicians,
Pharmacists and Patients as well as different meanings of cost (cost the system,
cost to the physician, and cost to the patient) choices per group of physicians lead
to very different decision points in each system and variations in sets of clinical
choices for similar patients. A random utility model is proposed. METHODS: Data
are extracted from the endep/biomed database for 600 physicians, transcripts from
qualitative focus groups and estimates from the centralized database of 6 patients’
surveys on cost of medicines (www.endeplux.org). The thinking about cost is clas-
sified in Cost S (cost to the System), Cost Ph (cost to the Physician) Cost Pa (cost to
the Patient).The conceptual framework has been mainly developed from pair of
country comparisons, especially from the French, German and Italian physicians
analysis (Huttin, Andral; 2003; Atella et als; 2003; Brenner et als, 2002). RESULTS: A
comparative intercountry framework is used to weight differently combinations of
(Cost S, Cost Ph, Cost Pa) in the system. A generalization will be proposed with a list
of different possible combinations aCostSbCostPhCostPa for each physician ij
among N physicians in J Health financing systems. CONCLUSIONS: This research
step aims to propose a link between a research line on transaction cost politics and
several statistical developments for a stated revealed preference disease econo-
metric model. It will help to identify the type of random utility models that would
clearly model how variations of preferences from Physicians, Pharmacist, Patients
that could help to manage variations between different national health care fi-
nancing systems.
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OBJECTIVES: To uses Latent Transition Analysis (LTA) to assess the difference in
the change in severity of a Neurological disorder between patients in two treat-
ment groups. The patients in the study were assigned to one of two treatment
groups Active or Placebo over a period of 6 months and the results to a question-
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